Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
Robert I. Haddad(Georgetown University), Robert L. Ferris(University of Pittsburgh), Makoto Tahara(National Cancer Center Hospital East), Francis P. Worden(Georgetown University), Mark Lynch(Fluidigm (United States)), Jérôme Fayette(Université Claude Bernard Lyon 1), Nabil F. Saba(Emory University), Lisa Licitra(University of Milan), Everett E. Vokes(University of Chicago), A. Dimitrios Colevas(Cancer Institute (WIA)), Fernando Concha‐Benavente(UPMC Hillman Cancer Center), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Vijayvel Jayaprakash(Roswell Park Comprehensive Cancer Center), Stefan Kasper(Essen University Hospital), Li Li(The University of Texas MD Anderson Cancer Center), J. Guigay(Centre Antoine Lacassagne)
Cited by 98
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k